LENZ Therapeutics Inc (LENZ)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $120.03M
Last updated: Nov 17, 2026 at 4:43 PM ET
LENZ Therapeutics Inc (LENZ) Statistics
LENZ Therapeutics (LENZ) has a market cap of $120.03M and an enterprise value of $89.47M. It kept -1134.97% of revenue as net income over the last 12 months. Its share count is up 10.09% from a year earlier.
Total Valuation
Enterprise value is 25.46% below the market cap, as cash exceeds debt.
| Market Cap | $120.03M |
|---|---|
| Enterprise Value | $89.47M |
| Latest price (Nov 17, 2026) | $3.50 |
Key Dates
The next earnings report is expected on Mar 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 28, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 8.9x and 0.6x.
| P/S Ratio | 8.9x |
|---|---|
| Forward P/S | 8.3x |
| P/B Ratio | 0.6x |
Price Statistics
The stock is down 86.33% over 52 weeks and trades 5.91% below its 50-day average.
| Beta (1Y) | 2.17 |
|---|---|
| 52-Week Change | -86.33% |
| 1-Month Change | +6.06% |
| 3-Month Change | -28.86% |
| 6-Month Change | -47.37% |
| 5-Year Change | -96.58% |
| Total Return (1Y) | -86.33% |
| Total Return (3Y CAGR) | -33.15% |
| Total Return (5Y CAGR) | -42.78% |
| Return vs SPY (1Y) | -98.71% |
| Max Drawdown (1Y) | -90.58% |
| Max Drawdown (3Y) | -93.86% |
| Sharpe Ratio (1Y) | -2.42 |
| Correlation with SPY (1Y) | 0.35 |
| 50-Day Average | $3.72 |
| 200-Day Average | $7.12 |
| 52-Week Range | $2.80 to $32.13 |
| RSI (14 Days) | 46.7 |
| Average Volume (20 Days) | 1.23M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 11.66x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 11.66x |
|---|---|
| Quick Ratio | 11.39x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -73.06% and return on assets is -66.88% over the last 12 months.
| Return on Equity (ROE) | -73.06% |
|---|---|
| Return on Assets (ROA) | -66.88% |
| ROA (5Y Average) | -39.68% |
| ROIC (5Y Average) | -32.14% |
| Asset Turnover | 0.06x |
| Inventory Turnover | 0.50x |
| Receivables Turnover | 18.24x |
| Cash Conversion Cycle | -249 days |
Scores
LENZ has an Altman Z-Score of 0.28, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 0.28 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $12.36M over the last 12 months is down 29.64% from the 12 months before.
| Revenue | $12.36M |
|---|---|
| Revenue Growth (YoY) | -29.64% |
| Gross Profit | $10.13M |
| Operating Income | -$149.69M |
| Pretax Income | -$140.27M |
| Net Income | -$140.27M |
| Reported EPS (TTM) | -$4.49 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 91.54% of the $209.75M in total assets.
| Cash and Equivalents | $30.55M |
|---|---|
| Total Debt | $0 |
| Net Cash | $30.55M |
| Net Cash Per Share | $0.97 |
| Working Capital | $189.15M |
| Shareholder Equity | $192.00M |
| Book Value Per Share | $6.11 |
| Total Assets | $209.75M |
| Total Liabilities | $17.75M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$127.63M |
|---|---|
| FCF Per Share | -$4.06 |
| Depreciation and Amortization | $1.53M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -1211.17%.
| Gross Margin | 81.97% |
|---|---|
| Operating Margin | -1211.17% |
| Pretax Margin | -1134.93% |
| Net Margin | -1134.97% |
Dividends and Yields
LENZ does not pay a dividend.
| Buyback Yield | -111.24% |
|---|---|
| Shareholder Yield | -111.24% |
Stock Splits
The last split was a 1-for-7 reverse split on Mar 22, 2024.
| Last Split Date | Mar 22, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:7 |
Analyst Forecast
Consensus estimates put revenue growth at 30.74% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +30.74% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About LENZ
What is LENZ's market cap?
LENZ Therapeutics has a market cap of $120.03M. Its enterprise value, which adds debt and subtracts cash, is $89.47M.
How many shares of LENZ are outstanding?
LENZ Therapeutics has 31.42M shares outstanding. The count is up 10.09% from a year earlier.
Does LENZ pay a dividend?
No. LENZ Therapeutics does not pay a dividend.
How much debt does LENZ have?
LENZ Therapeutics has $0 of total debt and $30.55M of cash and equivalents, a net cash position of $30.55M.
LENZ pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors